Item 1.01. Entry into a Material Definitive Agreement
FirstFire Note Waiver and Amendment
On
Pursuant to the FF Amendment, FF waived the following defaults under the FF
Note: (i) the Company's failure to make amortization payments that were due on
each of
In addition, the FF Amendment amends the schedule of amortization payments under
the FF Note such that no amortization payment is due until
The FF Amendment also amends the FF Note such that no adjustment was made to the conversion price of the FF Note as a result of the Reverse Split.
The FF Note was filed by the Company on
White Lion Note Waiver
On
Under the terms of the WL Waiver, WL waives the Company's failure to maintain
the listing of its Common Stock on the OTC QB Venture Market. This waiver is
effective through and until
The WL Note was filed by the Company on
The foregoing descriptions of the FF Amendment and the WL Waiver do not purport to be complete and are qualified in their entirety by reference to the FF Amendment and the WL Waiver, copies of which are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2, respectively.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits. Exhibit Exhibit Description Number 99.1 Waiver and Amendment to Convertible Promissory Note, datedJanuary 13, 2021 , by and betweenRespireRx Pharmaceuticals Inc. andFirstFire Global Opportunities Fund LLC . 99.2 Waiver with Respect to 8% Fixed Promissory Note, datedJanuary 13, 2021 , by and betweenRespireRx Pharmaceuticals Inc. andWhite Lion Capital, LLC .
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
(Registrant) By: /s/Jeff E. Margolis Jeff E. Margolis SVP, CFO, Secretary and Treasurer
© Edgar Online, source